Neurodegeneration – News and Features

Resverlogix’s first in class drug illustrates early signal of transport of key amyloid marker from brain.

GENFIT, a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, announces a new Scientific Advisory Board consisting of internationally renowned experts.

The collaboration agreements focused on developing assays for drug discovery and evaluating known compounds as potentially new therapeutic for Huntington's disease.

Archer Pharmaceuticals, Inc. has been launched to use modern technologies for the identification of novel treatments for Alzheimer's disease.

Debiopharm Group announced that the first healthy elderly subjects have been randomised in a clinical bioequivalence bridging study, conducted in the United States under IND (Investigational New Drug).

Company has announced four ongoing studies evaluating Fx-1006A across multiple indications and genetic variations.

Researchers from the Nottingham’s two universities are joining forces to develop a simple blood test to diagnose Alzheimer’s disease.

The companies believe that the combination of GDNF gene with AMT’s gene therapy platform can allow the development of a long term treatment of Parkinson’s disease.

Researchers at UT Southwestern Medical Center have designed a way to improve electrical stimulation of nerves by outfitting electrodes with the latest in chemically engineered fashion: a coating of basic black, formed from carbon nanotubes.

Researchers have identified a protein they say appears to be a primary player in maintaining normal functioning of an important class of neurons.